# Qkine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/qkine

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.qkine.com
- Total disclosed funding: $2.8M
- Latest round: Series A (Apr 2, 2020)
- Investors on record: 4

## About

Qkine Ltd, based in the UK, is a biotechnology company that specializes in the production of high-purity, animal-free recombinant proteins for critical applications in life sciences, including stem cell research and regenerative medicine.Qkine Ltd, founded in 2016 and headquartered in Cambridge, UK, focuses on manufacturing recombinant proteins essential for life sciences research. The company was established by Catherine Elton and Marko Hyvönen. In November 2022, Qkine raised GBP 4.30 million in funding co-led by Downing Ventures and Parkwalk Advisors, bringing the total amount raised to GBP 4.30 million with a current valuation of GBP 9.766 million.Qkine specializes in the manufacturing of high-purity, animal-free recombinant proteins, including growth factors and cytokines vital for various life science applications. Their product line supports stem cell and organoid cultures, contributing to advancements in cellular agriculture, regenerative medicine, and bioprinting. Key offerings include FGF2-G3, a thermostable form of FGF-2, and other recombinant proteins like activin A and BDNF, ensuring consistent bioactivity essential for biological research. Qkine serves a diverse clientele, including academic institutions and biotech firms across Europe, North America, and parts of Asia, adhering to stringent quality standards for scientific research.Qkine generates revenue primarily through direct sales to research institutions and life sciences companies on a B2B basis. Clients place bulk orders for specialized growth factors and cytokines tailored to specific research requirements, with comprehensive documentation for regulatory compliance. Pricing varies based on product specifications and order quantities, with flagship products like the animal-origin free TGF-ß1 playing a crucial role in stem cell maintenance and differentiation protocols.In November 2022, Qkine Ltd secured GBP 4.30 million in funding aimed at expanding its research department and market presence. The company plans to develop new products tailored to life sciences applications and is targeting expansion into additional geographic markets. The funds will support the growth of research teams and further product development initiatives.

## Funding rounds

- Series A, Apr 2, 2020, $1.8M — Cambridge Enterprise, Parkwalk Advisors, Martlet Capital, O2h Ventures
- Series A, Apr 2, 2019, $0.7M — Cambridge Enterprise
- Seed, Mar 21, 2018, $0.2M — Cambridge Enterprise

## Investors

- Cambridge Enterprise — Seed, Series A
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Series A
- Martlet Capital (https://capitalatlas.ai/funds/martlet-capital) — Series A
- O2h Ventures (https://capitalatlas.ai/funds/o2h-ventures) — Series A